Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer

BACKGROUND: Pembrolizumab is approved for patients with metastatic, microsatellite instability (MSI)‐high or mismatch repair‐deficient (dMMR) solid tumors. However, very few men with prostate cancer were included in these initial studies. METHODS: We performed a single institution retrospective revi...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Med
Главные авторы: Tucker, Matthew D., Zhu, Jason, Marin, Daniele, Gupta, Rajan T., Gupta, Santosh, Berry, William R., Ramalingam, Sundhar, Zhang, Tian, Harrison, Michael, Wu, Yuan, Healy, Patrick, Lisi, Stacey, George, Daniel J., Armstrong, Andrew J.
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2019
Предметы:
Clinical Cancer Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6712455/
https://ncbi.nlm.nih.gov/pubmed/31270961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2375
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы